A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

H9H-MC-JBEG -

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as galunisertib administered in combination with the anti-programmed cell death-ligand 1 (PD-L1) antibody, durvalumab, in participants with refractory metastatic pancreatic cancer.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Pancreatic Cancer
What the trial is testing?
Durvalumab, Galunisertib
Could I receive a Placebo?
No
Enrollment Goal
37
Trial Dates
Jun 15, 2016 - Apr 17, 2019
How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.